DFTX

#1289
Definium Therapeutics, Inc. - Common Shares
40.9 8 USD
-0.06%
Market Price
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
40.98
40.98
Yıllık Aralık
14.62
49.70
Günlük Değişim
-6.48%
Aylık Değişim
-8.89%
6 Aylık Değişim
+144.51%
Yıllık Değişim
+171.21%
Önceki Kapanış
43.8 2
Open
40.9 8
Düşük
40.9 8
Yüksek
40.9 8
Hacim
196
Tam grafiği aç

Financials

Genel Bakış Tablolar İstatistikler Documents

2026

Current report, Q3 FY2026
Definium Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Definium Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Definium Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K

Definium Therapeutics, Inc. current report, Q3 FY2022

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Mind Medicine (MindMed) Inc. (MNMD) on August 26, 2022. The filing addresses a material corporate action involving a reverse share split. Note: The request metadata references "Definium Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Mind Medicine (MindMed) Inc.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure adjustments rather than financial performance results.

Material Changes

  • Reverse Share Split: The Board approved a one-for-fifteen (1-for-15) reverse share split of outstanding common shares.
  • Effective Date: The split became effective after market close on August 26, 2022.
  • Trading Resumption: Trading on a split-adjusted basis began on August 29, 2022, on the Nasdaq Stock Exchange and NEO Exchange Inc.
  • Fractional Shares: No fractional shares were issued. Fractions less than 1/2 were cancelled; fractions of 1/2 or more were rounded up to one whole share.
  • Security Identifiers: Common shares were assigned a new CUSIP (60255C885) and ISIN (CA60255C8850). Listed warrants retained their symbols but received new CUSIP and ISIN numbers.
  • Equity Plans: The number of shares available for future grants and the terms of outstanding awards (including exercise prices) under stock option and equity incentive plans were adjusted to reflect the split.

Guidance, Outlook, and Risks

The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard disclosure regarding the share consolidation. The primary purpose of the filing is to disclose the execution of the previously announced reverse split.

Investor Verification Checklist

  • Verify the new CUSIP (60255C885) and ISIN (CA60255C8850) for common shares in brokerage accounts.
  • Confirm the adjusted number of shares held post-split and the treatment of any fractional shares (cancellation vs. rounding).
  • Review the updated terms of any outstanding stock options or equity awards, specifically the adjusted exercise price and share count.
  • Check the trading status of listed warrants (MMED.WA, MMED.WR, MMED.WS) and their new CUSIP/ISIN assignments.